Breaking Nomi Health Data Shows Diabetes Is No Longer the Top Driver of Rising U.S. Healthcare Costs

June 17, 2025 05:51 AM AEST | By EIN Presswire

Google News:

Recent News

Australia Share Market: Renewable Energy Stocks Driving ASX 200 Transf...

ADNOC’s Interest in Santos Stirs Regulatory Attention on ASX 200 and A...

Mizuho remains bullish on data centers; DLR remains top pick

Macquarie Group’s Role in the Expanding Australia Share Market

SALT LAKE CITY, UT, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- After decades of relentless increases, diabetes-related healthcare costs have plateaued. That’s the key finding from a new analysis by Nomi Health, marking a rare moment of opportunity for self-funded employers to re-evaluate how they manage one of their highest-cost conditions before the next wave of expenses hits.

In its latest Trends in Spend report, Nomi Health analyzed employer-sponsored claims data from 2021–2024 and found that, while overall healthcare costs continue to climb, diabetes spending has leveled off—ending a decades-long trend of rising costs.

“For years, diabetes has been one of the biggest and fastest-growing costs for employers,” said Mark Newman, CEO and Co-Founder of Nomi Health. “Now that those costs are holding steady, it’s the right time to take a closer look at what’s working—and do more of it.”

Key Findings from the Report:
• Annual spend for diabetics increased just 11% from 2021-2024, while spend for non-diabetics jumped 15%
• Average monthly medical spend for diabetics decreased slightly (0.5%), while non-diabetic medical spend surged 17%
• Prescription growth for diabetics (34%) stayed well below the 57% spike for non-diabetics

What’s Driving the Shift?

Three major trends:
• More people are using new GLP-1 drugs for diabetes and weight loss.
• Most PBMs now cap insulin costs at $35 per month.
• More employers are using diabetes programs that help people stay out of the hospital.

But Nomi Health also raises a caution about what they call the “GLP-1 paradox.” These drugs help now, but they’re costly over time and their health benefits may depend on continued use. Employers need a strategy.

Window Of Opportunity
With costs holding steady and new tools available, this is a good time for employers to review their plans. The report encourages them to act before spending starts rising again.

Read the full report here.

About Nomi Health
Nomi Health is rebuilding healthcare through its direct model. Founded in 2019, the company’s integrated platform combines analytics, pharmacy management, direct provider networks and payment solutions - providing the infrastructure that powers better healthcare for self-insured employers. The company serves 4,000 customers nationwide, impacting 30 million lives and influencing over $150 billion in healthcare spend. Based in Orem, Utah, Nomi Health leads the movement to rebuild America's healthcare system.

Rebeca Damico
Kronus Communications
+1 385-887-1641
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.